Gilead Sciences to acquire UK-based privately-held biotech MiroBio for $405M
Justin Sullivan


Gilead Sciences (NASDAQ:GILD) on Thursday said it would buy UK-based privately-held biotech MiroBio for about $405M in cash.
GILD said the deal will reduce its 2022 GAAP and non-GAAP EPS by about $0.30-$0.35.
The acquisition will provide GILD with MiroBioâs proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists.

MiroBio's approach to restoring immune balance to treat autoimmune diseases complements Gilead's (GILD) inflammation research and development strategy, the U.S. company said in a statement.
MiroBio's lead investigational antibody, called MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator and has entered phase 1 clinical trials.
Gilead's (GILD) acquisition of MiroBio comes two days after it announced strong Y/Y sales results in its HIV and oncology franchises and raised its 2022 guidance, sending its shares up nearly 5%
yesterday.
GILD stock was marginally lower in premarket trading on Thursday.